Tyrosine Kinase Inhibitors as Initial Therapy for Patients With Chronic Myeloid Leukemia in Accelerated Phase.

Tyrosine Kinase Inhibitors as Initial Therapy for Patients With Chronic Myeloid Leukemia in Accelerated Phase. Clin Lymphoma Myeloma Leuk. 2013 Dec 9; Authors: Ohanian M, Kantarjian HM, Quintas-Cardama A, Jabbour E, Abruzzo L, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Champlin R, Pierce S, Alattar ML, Trinh LX, Luthra R, Ferrajoli A, Kadia T, O'Brien S, Cortes JE Abstract BACKGROUND: Accelerated phase CML most frequently represents a progression state in CML. However, some patients present with AP features at the time of diagnosis. There is limited information on the outcome of these patients who received TKIs as initial therapy. PATIENTS AND METHODS: We analyzed the outcome of 51 consecutive patients with CML who presented with features of AP at the time of diagnosis, including blasts ≥ 15% (n = 6), basophils ≥ 20% (n = 22), platelets 
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Related Links:

AbstractRisk-stratification is an essential management tool in defining prognosis of haematological neoplasms, both from patient and physician perspective. We define a new prognostic term “Dynamic Response Assessment Method(s) (DRAM)” as “method(s) used for re-stratifying disease prognosis at fixed intervals during the treatment course”. The risk stratification is done after a fixed duration of treatment or chemotherapy cycles using sensitive techniques. The information obtai ned then can be used for further therapeutic decisions and prognostication. Currently, there is enough evidence that response...
Source: Indian Journal of Hematology and Blood Transfusion - Category: Hematology Source Type: research
ConclusionHalving time of BCR-ABL1appears promising in prediction of outcome in CML
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
This study aims to evaluate the molecular response to generic Imatinib in Iranian patients with CML.MethodsThis prospective study consisted of 255 newly-diagnosed CML patients received imatinib. Molecular response was analyzed at 3 and 6 months from the start of the treatment and then every six months, and long-term outcomes included overall survival (OS ) and progression free survival (PFS) were evaluated.ResultsAt a median follow-up of 34.8 months (range: 3-84 (the OS and PFS at 7 years were 94.3% and 92.9%, respectively. Eighty-four months PFS rates in patients with a BCR-ABL IS ≤10% at 3rd months and BCR-ABLIS ≤1...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
We report results of preclinical studies and clinical trials, and discuss the mechanism of action of SINEs and their effects in multiple myeloma, non-Hodgkin lymphomas, lymphoblastic leukemia, and acute and chronic myeloid leukemia. In the future, the numerous experimental studies currently underway will allow us to define the role of SINEs and will possibly permit these substances to be introduced into daily clinical practice.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
We reported results of preclinical studies and clinical trials and discussed the mechanism of action of SINEs and their effects in multiple myeloma, non-Hodgkin lymphomas, lymphoblastic leukaemia, acute and chronic myeloid leukaemia.In the next future the numerous experimental studies currently underway will allow us to define the role of the SINEs and the possibility of introducing these substances into daily clinical practice.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionsDose reduction was observed in 65.9% of the patients at their last visit; except imatinib, TKI dose densities were
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
We report results of preclinical studies and clinical trials, and discuss the mechanism of action of SINEs and their effects in multiple myeloma, non-Hodgkin lymphomas, lymphoblastic leukemia, and acute and chronic myeloid leukemia.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Source Type: research
We reported results of preclinical studies and clinical trials and discussed the mechanism of action of SINEs and their effects in multiple myeloma, non-Hodgkin lymphomas, lymphoblastic leukaemia, acute and chronic myeloid leukaemia.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Article Source Type: research
We investigated tyrosine kinase inhibitor (TKI) dosing patterns and survival in elderly chronic myeloid leukemia (CML) patients: Approximately 66% of 378 patients were on reduced TKIs dose at last visit; except imatinib, dose densities were
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
ConclusionsResults of this study with long-term follow-up are further evidence of that the generic imatinib is at least non-inferior to the original imatinib regarding efficacy and survival both when used initially or as a subsequent replacement for original imatinib.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Chronic Leukemia | Chronic Myeloid Leukaemia | Gleevec | Leukemia | Lymphoma | Myeloma | Nilotinib | Tasigna